Bristol-Myers Squibb Co. is joining Foundation Medicine to use the company’s extensive genomic profiling and molecular information solutions to identify predictive biomarkers in patients in clinical trials that are analyzing Bristol-Myers Squibb’s cancer immunotherapies, Bristol-Myers Squibb said in a press release.
Used to identify a tumor and its
microenvironment, biomarkers like Microsatellite Instability and Tumor
Mutational Burden can uncover immune-related mechanisms that can show how a cancer
patient responds to immunotherapy, Bristol-Meyers Squibb said.
“Translational medicine research is critical
to further our understanding of cancer biology and to identify which patient
populations are most likely to derive benefit from our immuno-oncology agents,” Dr. Fouad Namouni, head of Development, Oncology, at Bristol-Myers Squibb said in the release. “We believe this collaboration with Foundation Medicine
will help us better understand the relation of genomic approaches to
immunotherapy efficacy across a number of different tumor types and
Cancer immunotherapy supports the immune
system by boosting it with an anti-cancer response, which relies partly on the identification
of neoantigens, or cancer-specific proteins, Bristol-Myers Squibb said.
“Cancer immuno-therapy is evolving rapidly,
and biopharmaceutical companies and practicing oncologists alike may benefit
from a reliable, validated, comprehensive view of mutational burden and genomic
alterations to make the most informed care decisions,” Melanie Nallicheri,
chief business officer and head of biopharma for Foundation Medicine, said in the
release. “Our collaboration with Bristol-Myers Squibb highlights the potential value of
our molecular information platform to the biopharma industry for its ability to
inform, to reduce risk and to accelerate clinical development in this high
growth and highly competitive oncology field."
BMS, Foundation Medicine partner on predictive biomarker project